Home

Nesli Basgoz

CIK 1361580 · last filed 2020-05-12

Nesli Basgoz is a corporate insider who has filed 39 SEC Form 4 insider transactions across 3 companies since 2007. Across all open-market trades the lifetime net is −$3.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $211.2K across reported positions. 29 SEC filings were submitted jointly with Actavis plc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$211.2K

Companies

3

Total Filings

39

Lifetime Open-Market Net

-$3.05M

Filer Profile

Reported Address
C/O FOREST LABORATORIES, INC.
909 THIRD AVENUE
NEW YORK, NY 10022
Related Filers
Actavis plc — 29 joint filings, latest 2020-05-12
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Allergan plc (AGN) Delisted Director 6,888 — — -$1.73M 22 2020-05-04
ACT Director 4,286 $49.27 $211.2K -$655.4K 2 2015-06-10
Forest Laboratories, LLC (FRX) Delisted Director 8,256 $12.00 $99.1K -$666.1K 10 2013-08-16

Recent Filings

39 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-05-12 — Disp (D) −6,888 $0
2020-05-04 Allergan plc (AGN) Delisted Mixed −1,271 -$188.0K EDGAR
2019-12-09 Allergan plc (AGN) Delisted Gift (G) −47 $0 EDGAR
2019-05-02 Allergan plc (AGN) Delisted Mixed +1,111 $159.9K EDGAR
2018-09-04 Allergan plc (AGN) Delisted Mixed −1,318 -$200.5K EDGAR
2018-08-14 Allergan plc (AGN) Delisted Mixed +1,055 -$145 EDGAR
2018-05-04 Allergan plc (AGN) Delisted Grant (A) +1,985 $299.9K EDGAR
2018-05-03 Allergan plc (AGN) Delisted Tax (F) −588 -$89.9K EDGAR
2017-12-26 Allergan plc (AGN) Delisted Mixed −68 $3.1K EDGAR
2017-05-22 Allergan plc (AGN) Delisted Mixed — -$256.9K EDGAR
Showing 1–10 of 39
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.